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Abstract
Background: Sporadic Parkinson’s disease (PD) is a progressive neurodegenerative disorder with unknown cause, but it has
been suggested that neuroinflammation may play a role in pathogenesis of the disease. Neuroinflammatory component in
process of PD neurodegeneration was proposed by postmortem, epidemiological and animal model studies. However, it
remains unclear how neuroinflammatory factors contribute to dopaminergic neuronal death in PD.
Findings: In this study, we analyzed the relationship among inducible nitric oxide synthase (iNOS)-derived NO,
mitochondrial dysfunction and dopaminergic neurodegeneration to examine the possibility that microglial neuroin-
flammation may induce dopaminergic neuronal loss in the substantia nigra. Unilateral injection of lipopolysaccharide (LPS)
into the striatum of rat was followed by immunocytochemical, histological, neurochemical and biochemical analyses. In
addition, behavioral assessments including cylinder test and amphetamine-induced rotational behavior test were employed
to validate ipsilateral damage to the dopamine nigrostriatal pathway. LPS injection caused progressive degeneration of the
dopamine nigrostriatal system, which was accompanied by motor impairments including asymmetric usage of forelimbs
and amphetamine-induced turning behavior in animals. Interestingly, some of the remaining nigral dopaminergic neurons
had intracytoplasmic accumulation of a-synuclein and ubiquitin. Furthermore, defect in the mitochondrial respiratory chain,
and extensive S-nitrosylation/nitration of mitochondrial complex I were detected prior to the dopaminergic neuronal loss.
The mitochondrial injury was prevented by treatment with L-N
6-(l-iminoethyl)-lysine, an iNOS inhibitor, suggesting that
iNOS-derived NO is associated with the mitochondrial impairment.
Conclusions: These results implicate neuroinflammation-induced S-nitrosylation/nitration of mitochondrial complex I in
mitochondrial malfunction and subsequent degeneration of the nigral dopamine neurons.
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Introduction
Microglial activation is a pathological hallmark of neurodegen-
erative diseases including Parkinson’s disease (PD) [1]. Microgliosis
is a normal response in the damaged CNS, which can promote
sprouting of injured neurons by providing neurotrophic factors
[2]. On the other hand, the activated microglia may be destructive
to neurons by releasing inflammatory molecules such as nitric
oxide (NO), and cytokines [3,4]. While the role of activated
microglia in the parkinsonian brain is controversial, the observa-
tion of persistent microgliosis in the substantia nigra of
parkinsonian patients, and 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine-exposed humans and animals has led to a postulation that
the chronic inflammatory response might contribute to loss of the
dopamine neurons [5–8]. A study using positron emission
tomography with [
11C](R)-PK11195, a radiotracer for activated
microglia and [
11C]CFT, a dopamine transporter marker reported
that microglial activation level in the midbrain is positively
correlated with severity of motor impairment and dopaminergic
terminal loss in the putamen of early PD patients, suggesting
microglial neuroinflammatory response may be related to
progressive neurodegeneration of the disease [9]. In line with the
observation, an epidemiological study illustrated that the risk of
developing PD is significantly reduced by regular use of non-
steroidal anti-inflammatory drugs such as ibuprofen [10]. In
addition, reactive microglia express increased levels of inflamma-
tory enzymes including inducible nitric oxide synthase (iNOS) and
cyclooxygenase-2 in the substantia nigra of PD brain [11].
Importantly, these enzymes appear to play a pivotal role in the
loss of dopaminergic neurons in animal models of PD [12–14].
iNOS is expressed in microglia during neuroinflammation and
produces excessive amount of NO, which can cause death of
neurons [15]. The gaseous molecule released at extramitochon-
drial sites can diffuse into the mitochondria and react with
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which accounts for much of the disruption of mitochondrial
function [16]. Moreover, peroxynitrite inhibits the activity of
manganese superoxide dismutase, which could enhance formation
of superoxide anion and peroxynitrite [17]. It has been
documented that NO and its metabolite peroxynitrite inhibit
mitochondrial respiration via S-nitrosylation and nitration of
complex I, respectively [18]. Impairment in the mitochondrial
electron transport chain has been suggested to be a critical factor
in the pathogenesis of PD, as defect in mitochondrial complex I is
consistently detected in PD patients [19,20] and mitochondrial
toxins induces parkinsonism [21–23]. The dopaminergic neurons
can be particularly susceptible to NO neurotoxicity because
dopamine potentiates NO-induced impairment in mitochondrial
respiration [24]. Furthermore, metabolism of dopamine by
monoamine oxidase, a mitochondrial enzyme may enhance the
mitochondrial lesion in the dopamine-producing neurons [25].
We and other groups have demonstrated that intranigral [26–
28] or intrapalidal [29] lipopolysaccharide (LPS) induces death of
the nigral dopaminergic neurons through microglial activation.
However, these animal models did not recapitulate some cardinal
features of PD such as progressive dopaminergic neurodegener-
ation, Lewy body-like intracytoplasmic inclusion and parkinsonian
behavioral impairments. Furthermore, underlying mechanism(s)
by which microglial neuroinflammation kills the nigral dopami-
nergic neurons has not been fully delineated. This study was
designed to demonstrate striatal neuroinflammation-induced
dopaminergic neurodegeneration and explore how neuroinflam-
mation mediates the loss of dopamine-producing neurons. Here,
we report that LPS-induced striatal inflammation causes the
impairment of the mitochondrial respiratory chain in both the
substantia nigra and striatum, which was followed by progressive
degeneration of the dopamine nigrostriatal pathway, behavioral
impairment, and accumulation of a-synuclein and ubiquitin in the
remaining nigral dopaminergic neurons. In addition, our results
indicate that NO produced by iNOS is related to S-nitrosylation/
nitration of mitochondrial complex I which might lead to
mitochondrial dysfunction and the subsequent dopaminergic
neurodegeneration.
Methods
Animals and surgery
All animal experiments were performed according to the NIH
Guide for the Care and Use of Laboratory Animals and were approved
by the University of Kentucky Institutional Animal Care and Use
Committee. 3 month-old male Sprague-Dawley rats (Harlan,
Indianapolis, IN) were housed under a twelve hour light-dark cycle
with free access to food and water in the Division of Lab Animal
Resources at the University of Kentucky. For the injection of LPS
(Salmonella minnesota; Sigma-Aldrich, St Louis, MO), rats were
deeply anesthetized with sodium pentobarbital (50 mg/kg i.p.) and
were positioned in a stereotaxic frame (Stoelting Co., Wood Dale,
IL) with the incisor bar at the level of the ear. LPS dissolved in
saline (2.5 mg/ml) was injected into the right striatum (3 ml/site)
using the following coordinates (in mm): site 1, anteroposterior
(AP) 1.0, mediolateral (ML) 2.0, dorsoventral (DV) 25.5; site 2,
AP 1.0, ML 3.5, DV 26.0; site 3, AP 20.5, ML 2.5, DV 25.0; site
4, AP 20.5, ML 4.0, DV 26.5. Saline was injected into the left
striatum with parallel coordinates. Placebo animals received saline
injections into the right and left striatum with the same regimen.
After surgery, animals were kept on heating pad until recovery
from surgery and subcutaneous saline was given for aid in post-
operative recovery. In order to investigate the detrimental effect of
iNOS on the mitochondria, animals were treated with L-N
6-(l-
iminoethyl)-lysine (L-NIL, 5 mg/ml/kg, i.p., Cayman Chemical,
Ann Arbor, MI) or its vehicle (sterilized saline) 20 min before, and
one day and two days after LPS injection.
Histopathology
Animals were perfused with 4% paraformaldehyde three days,
one week, two weeks, and four weeks after LPS injections (n=5–
6/group) for immunohistochemistry and histopathological exam-
inations. Coronal sections (30 mm) were cut through the entire
brain using a sliding microtome. Immunohistochemistry, with
slight modifications, was performed as previously described [28].
Briefly, every sixth section from the region containing the striatum
or substantia nigra was blocked with 5% bovine serum albumin for
1 hr at room temperature. The brain sections were immunola-
beled with antibody to tyrosine hydroxylase (TH, Calbiochem,
San Diego, CA, 1:3,000), MHC class II (OX-6, Serotec, Raleigh,
NC, 1:1,000) or dopamine- and cAMP-regulated phosphoprotein
polypeptide (DARPP-32, Chemicon, Temecula, CA, 1:1,000,
24 hrs at 4uC). After multiple washings, sections were incubated
with species-appropriate secondary antibody (1:1,000; Vector
Laboratories, Burlingame, CA). The final antigen-antibody
complex was visualized using an Avidin-biotin complex (ABC
kit, Vector laboratories) method and 3,39-diaminobenzidine
tetrachloride as a chromagen (Sigma-Aldrich).
Colocalization of TH with a-synuclein, or ubiquitin was
assessed as previously described [29]. Briefly, substantia nigra-
containing sections were incubated with primary polyclonal
antibody against a-synuclein (1:500; Sigma-Aldrich) or ubiquitin
(1:1,000; Sigma-Aldrich) overnight at 4uC. The sections were
incubated in Alexa Fluor 488 goat anti-rabbit secondary antibody
(1:1,000; Molecular Probes Inc., Eugene, OR) for 1 hr, at room
temperature. The sections were subsequently incubated with
mouse anti-TH primary antibody (1:1,000; Calbiochem) overnight
at 4uC followed by incubation for 1 hr in Alexa Fluor 568 goat
anti-mouse IgG secondary antibody (1:1,000; Molecular Probes
Inc.) at room temperature. The fluorescent specimens were first
assessed by an Axioplan 2 microscope (Carl Zeiss, Inc.) and images
were acquired by using an Axiocam digital camera connected to a
computer equipped with Axiovision 3.0 software (Carl Zeiss, Inc.).
Fluorescent preparations were also examined using the Leica TCS
SP laser scanning confocal imaging system (Leica Microsystems,
Inc., Buffalo, NY). Images were viewed on a Leica DM RXE
upright microscope. Photomicrographs were captured simulta-
neously for both fluorophores [Alexa Fluor 488 (green) and Alexa
Fluor 568 (red)] by using argon and krypton lasers, respectively.
Regions exhibiting colocalization of the red and green emitters
produced yellow fluorescence.
Another set of sections were rinsed in PBS and then incubated
in PBS containing proteinase K (20 mg/ml) for 30 mins at room
temperature. After multiple washings in PBS, these sections were
subjected to immunostaining with antibodies to a-synuclein
(1:5,000, Chemicon, Temecula, CA) or ubiquitin (1:5,000,
Sigma-Aldrich).
Standard Nissl staining was performed to assess neuronal
morphology and population in the substantia nigra. Degenerative
neuronal cell bodies and neurites in the substantia nigra and
striatum were visualized using the FD Neurosilver kit (FD
NeuroTechnologies, Ellicott City, MD), which was performed
according to the manufacturer’s protocol. Photomicrographs were
taken by using an Axiocam digital camera connected to a
computer equipped with Axiovision 3.0 software (Carl Zeiss, Inc.,
Thornwood, NY).
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The number of TH-positive neurons in the substantia nigra was
determined using the computerized optical fractionator method of
the Bioquant system (Memphis, TN, USA), which was described
previously [30,31]. Striatal TH-positive fiber density was mea-
sured as previously described [32]. Briefly, striatum-containing
sections were picked at seven rostrocaudal levels, covering the
entire head and tail of the striatum, corresponding to: (i) AP +1.60;
(ii) AP +1.00; (iii) AP+0.20; (iv) AP 20.30; (v) AP 20.90; (vi) AP
21.40 and (vii) AP 22.10 relative to bregma. TH-positive fiber
density was measured by using Bioquant Image Analysis software.
Each value was corrected for non-specific background by
subtracting the optical density of corpus callosum.
HPLC analysis for levels of striatal neurochemicals
Animals were killed four weeks following LPS challenge for
determination of striatal dopamine, serotonin and their metab-
olites levels (n=7/group). Levels of striatal dopamine, 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA),
serotonin, and 5-hydroxyindole acetic acid (5-HIAA) were
determined by using HPLC. Analyses were performed as
previously described [33]. Briefly, tissue samples were sonicated
in 300 ml of cold 0.1 M perchloric acid containing dihydrox-
ybenzylamine as an internal standard. The supernatant was
separated by centrifugation at 12,000 g for five minutes, and was
transferred to Millipore Ultrafree centrifugal filters (pore size,
0.22 mm), and then were spun at 12,000 g for one minute. The
filtrate was diluted with HPLC mobile phase, and 50 mlw a s
injected onto the HPLC column. The HPLC system consisted of
a Beckman Model 507 autoinjector, a Beckman Model 118
pump, and an ESA Model 5200A Coulochem II electrochemical
detector with a Model 5011 dual-detector analytical cell (detector
1 set at +350 mV and detector 2 set at 2300 mV). An ESA
Hypersil ODS 3 mm particle C18 column (8064.6 mm) was used
for separations. Flow rate was 1.4 ml/min and the mobile phase
was a pH 4.1, 0.17 M citrate–acetate buffer (containing 5 mg/l
EDTA, 70–80 mg/l octanesulfonic acid, and 7–8% methanol).
Chromatograms were recorded from both detectors using two
dual-channel strip chart recorders. Retention times of standards
were used to identify peaks, and peak heights were used to
calculate recovery of internal standard and amount of dopamine
and metabolites. Tissue monoamine concentrations of dopamine,
DOPAC, HVA, serotonin, and 5-HIAA are expressed as ng/mg
wet tissue.
Behavioral assessment
Test for amphetamine-induced rotational behavior was per-
formed four weeks following LPS injection (n=5–6/group). For
the test, animals were placed in a hemispherical bowl immediately
after receiving 5 mg/kg amphetamine injection (i.p.). The
behavior of each animal was monitored through an automated
video-tracking system, and the number of ipsilateral 360u turns
was determined for 90 minutes per animal.
Cylinder test is a motor assessment of forelimb asymmetry, and
was performed as described previously with slight modifications
[34]. Briefly, rats were individually put into a glass cylinder
(20 cm diameter, 34 cm height) and were video recorded until
they touched the cylinder wall with their forelimbs 20 times. The
recordings were analyzed by an investigator who was not aware
of the identity of the rats. The data are presented as the
asymmetric score calculated by the following formula: (Right
touch2Left touch)/(Right touch+Left touch+Both touch)(n=5–
6/group).
Mitochondrial isolation and measurement of their
respiration
Mitochondria were isolated using discontinuous Ficoll gradient
and differential centrifugation with nitrogen disruption, and
respiration was assessed as previously described with slight
modifications [35]. Briefly, rats were killed three days after LPS
injections and the nigral and striatal tissues were immediately and
carefully dissected. Two unilaterally injected striata or four nigra,
ipsilateral to the injections, had to be pooled to obtain one sample
(n=6–9/group). The tissues were homogenized with ice-cold
isolation buffer (pH 7.2, 215 mM mannitol, 75 mM sucrose, 0.1%
bovine serum albumin, 20 mM HEPES, 1 mM EGTA) and the
crude mitochondrial fraction was obtained by differential
centrifugation and nitrogen disruption. Further purification was
performed using a Ficoll gradient and differential centrifugation.
Mitochondrial respiratory rates were measured using a Clark-type
electrode in a continuously stirred and sealed thermostatically
controlled chamber (Oxytherm System, Hansatech Instruments
Ltd., King’s Lynn, Norfolk, UK) maintained at 37uC. 25 to 40 mg
of isolated mitochondrial protein was placed in the chamber
containing 250 ml of KCl-based respiration buffer (125 mM KCl,
2 mM MgCl2, 2.5 mM KH2PO4, 0.1% BSA, 20 mM HEPES at
pH 7.2) and allowed to equilibrate for 1 min. State II respiration
was initiated by the addition of complex I substrates, pyruvate
(5 mM) and malate (2.5 mM), to monitor. Then ADP (150 mM)
were added to the mitochondria to assess state III respiratory rate
for 2 mins, followed by the addition of oligomycin (2 mM) to
monitor state IV respiration rate for an additional 2 mins. For the
measurement of uncoupled respiratory rate, FCCP (2 mM) was
added to the mitochondria in the chamber and oxygen
consumption rate was measured for another 2 mins. This was
followed by the addition of succinate (10 mM) to monitor complex
II-driven respiration. The results were the rates of oxygen
consumption in nanoatoms of oxygen/min/mg protein and
presented as percentage of control.
Assessment of mitochondrial protein S-nitrosylation/
nitration
Approximately, 200 mg of mitochondrial protein was solubilized
in RIPA buffer containing 1% lauryl maltoside (Sigma-Aldrich)
and centrifuged at 20,000g for 30 min to collect the supernatant.
The mitochondrial solution was incubated at 4uC for 24 hr with
15 ml of agarose beads, irreversibly cross-linked to complex I
specific antibodies (MitoSciences, Eugene, OR). The beads were
collected by centrifugation and washed three times with PBS
containing 0.05% laruryl maltoside. The beads were then
resuspended in 50 ml of sample loading buffer with non-reducing
condition and agitated for 10 min. After gentle centrifugation,
10 ml of the supernatant was loaded into a 12% SDS-PAGE gel
and proteins were resolved. The proteins were transferred to
PVDF membrane and detected by incubation with a polyclonal
antibody against 3-nitrotyrosine (Upstate Biotechnology, Lake
Placid, NY) or S-nitrosylcystein (Sigma-Aldrich), which was
followed by horseradish peroxidase labeled goat anti-rabbit IgG
(Sigma-Aldrich). Chemiluminescent detection with the ECL Plus
kit and exposure to x-ray film was performed, and protein levels
were quantified by the Scion Image software (Scion Corporation,
Frederick, MD) (n=4/group).
Western blot analysis
Animals were sacrificed six hours, one day, and three days after
LPS or saline injections. The striatum and substantia nigra were
dissected out on ice. Tissues were homogenized in ice-cold lysis
Nitric Oxide and Parkinsonism
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the samples were kept at 270uC until they were used for analysis.
Next, 15 mg of protein from each sample was aliquoted, and after
addition of loading buffer, the protein was loaded and resolved
using a 12% SDS-PAGE gel. Protein on the gel was transferred to
a nitrocellulose membrane, which was blocked in 5% fat-free milk
at 4uC overnight. The membrane was incubated in primary
antibodies to iNOS (1:1,000, Upstate Biotechnology) or DARPP-
32 (1:4,000) at room temperature for one hour. Then, the
membrane was rinsed with tris-buffered saline three times for
15 min each before incubation in secondary antibody (goat anti-
rabbit, 1:2,000; Sigma-Aldrich) for one hour. This was followed by
treatment with the ECL chemiluminescent reagents (Amersham
Biosciences, Piscataway, NJ) and exposure to film. A density
measurement for each band was performed with the Scion Image
software (Scion Corporation). Background values from an
equivalent area near each lane were subtracted from each band
to calculate mean band density and iNOS or DARPP-32
immunoreactivity was normalized by density of b-actin bands in
the same membrane to correct loading error (n=3–4/group).
Statistical analysis
Animals were randomly grouped, and tests of variance
homogeneity, normality, and distribution were performed to
ensure that the assumptions required for standard parametric
analysis of variance (ANOVA) were satisfied. The Systat 10
software (SPSS Inc., Chicago, IL) was used to perform statistical
analyses by using the linear correlation unpaired test, Student’s t-
test or ANOVA followed by a protected least significant
differences post hoc test only following a positive F test result.
Statistical significance was set at p,0.05. The linear correlation
unpaired test was performed to analyze correlation between loss of
nigral TH-positive cells and time. The ANOVA was used for
analysis of the stereological cell counts, mitochondrial respiration
data, RNase protection assay, and western blot. The Student’s t-
test was used to analyze HPLC and behavioral data. Data are
expressed as means 6 s.e.m.
Results
1. Progressive degeneration of the dopamine
nigrostriatal system
To characterize and quantify the loss of dopaminergic neurons
in the midbrain after LPS injection, immunostaining with an
antibody against TH and non-biased stereological estimation of
the TH-positive neurons in the substantia nigra were performed.
Abundant TH-positive cell bodies and fibers existed in the
substantia nigra and ventral tegmental area of placebo and
Figure 1. Progressive degeneration of the nigral dopaminergic neurons after intrastriatal LPS. (A) Representative TH immunostaining of
coronal midbrain sections demonstrates that the numbers of TH-positive neurons and fibers in the substantia nigra pars compacta are gradually
reduced by intrastriatal LPS injection. Note that TH-positive neurons in the medial substantia nigra pars compacta and ventral tegmental area are
spared; scale bar: 200 mm. (B) Stereological cell counts of the TH-positive neurons in the substantia nigra pars compacta (n=5–6/group, ** p,0.01,
*** p,0.001). (C) The substantia nigra pars compacta is outlined with an orange dashed line (top). High magnification image of Nissl stainings
suggest loss of the nigral dopaminergic neurons, at four weeks following LPS injection (bottom); scale bar: 200 mm. (D) Silver staining is hardly seen in
the substantia nigra ipsilateral to vehicle treatment. However, abundant silver grain-deposits are observed in the neurons (arrows) and fibers (arrow
heads) in the substantia nigra ipsilateral to the intrastriatal LPS injections, indicating there is ongoing neurodegenerative process in the region. Scale
bar: 20 mm.
doi:10.1371/journal.pone.0005482.g001
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and fibers progressively decreased in the substantia nigra
ipsilateral to the LPS injection, while TH-positive neurons in the
ventral tegmental area were spared (Fig. 1A). Stereological
estimation of the spared nigral TH-positive cells showed a
progressive and significant loss of the cells: 21% at one week
(p=8610
23), 38% at two weeks (p=1610
25), and 41% at four
weeks (p=2610
27; Fig. 1B). Stereological analysis indicated that
the number of TH-positive cells in the ventral tegmental area was
not significantly affected by LPS injection (98.962.9% at one
week, 100.267.1% at two weeks and 97.367.4% at four weeks vs.
control). Nissl staining of adjacent sections showed fewer large
neurons in the substantia nigra, consistent with the loss of
dopaminergic neurons four weeks after LPS injection (Fig. 1C). To
detect ongoing degenerative events of the nigrostriatal dopami-
nergic system, silver staining was performed. No nigral degener-
ation was detected in the substantia nigra ipsilateral to the vehicle-
injected striatum (Fig. 1D). However, nigral neurons with silver
deposits in their cell bodies or fibers were observed in the
substantia nigra ipsilateral to the LPS-injected side (Fig. 1D). In
addition to the loss of dopaminergic cell bodies in the substantia
nigra, silver staining of striatal sections revealed that axon
terminals were undergoing degeneration by LPS-induced inflam-
mation, as shown by dense staining with silver grains (Fig. 2A).
Density of striatal TH-positive fiber was also significantly reduced
four weeks after LPS injection (Fig. S1, 15%, p=0.001). In
contrast, the immunostaining for DARPP-32 indicated that the
population of gamma-aminobutyric acid (GABA) neurons in the
striatum did not seem to be affected by the LPS infusions (Fig. 2B,
top panel). In agreement with the immunostaining, expression
level of DARPP-32 was not significantly altered by LPS challenge
as determined by Western blot analysis (Fig. 2B, bottom panel).
Consistent with the degeneration of the nigrostriatal system, the
level of striatal dopamine significantly declined to 42% of the
control level, four weeks after LPS injection (p=1610
29). The
turnover ratio of DOPAC (p=1610
26) or HVA (p=1610
25)t o
dopamine was significantly increased, as occurs in PD [36]. There
was also a significant increase in HVA level (p=0.004) but not
DOPAC following LPS (Fig. 2C), suggesting an alteration in
dopamine metabolism. Serotonin but not its primary metabolite,
5-HIAA was also significantly decreased (p=0.0002) leading to a
significant increase in the turnover ratio (5-HIAA/serotonin;
p=2 610
25) (Fig. S2), which may indicate that serotonergic
neurons were affected by LPS infusion.
Figure 2. Axonal terminal degeneration in the striatum following intrastriatal LPS. (A) Silver staining reveals that there is no silver-positive
stained fibers in the vehicle treated striatum while an abundance of silver grain-deposits are observed in the LPS injected striatum, suggesting the
degeneration of axonal fibers (arrows). Scale bar: 20 mm. (B) Immunostaining for DARPP-32 shows that the GABAergic neurons are intact following
LPS injections. Western blot for DARPP-32 and its quantification indicate that there is no significant alteration in the expression of DARPP-32 after LPS
challenge. Scale bar: 200 mm. (C) HPLC analysis shows that intrastriatal LPS injection depletes 58% of the striatal dopamine relative to control at four
weeks. The DOPAC level is not affected; however, HVA is significantly increased. The turnover ratios of DOPAC/dopamine and HVA/dopamine are
dramatically increased (n=7/group; ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0005482.g002
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ubiquitin
One of the pathological hallmarks of PD is the formation of
Lewy bodies, a proteinaceous cytoplasmic inclusion containing a-
synuclein and ubiquitin [37]. Thus, we double immunostained
midbrain sections with antibodies to TH and a-synuclein, or TH
and ubiquitin to assess intracytoplasmic accumulations of these
proteins following striatal inflammation. Fluorescent microscopic
analysis of dual-stained TH and a-synuclein demonstrated
smeared immunostaining of a-synuclein in the neuronal cytoplasm
of the vehicle-injected side. However, an accumulation of a-
synuclein in the cytoplasm of surviving TH-positive neurons was
observed in the substantia nigra ipsilateral to the LPS injection
(Fig. 3A,B). Immunofluorescent staining also revealed that
ubiquitin accumulates in the spared dopaminergic neurons
following intrastriatal LPS injections (Fig. 3C). In an attempt to
visualize insoluble form of a-synuclein or ubiquitin, we pretreated
midbrain sections with proteinase K, and then immunostained
with antibodies against a-synuclein or ubiquitin. Intrastriatal LPS
injection increased the immunoreactivity of a-synuclein (Fig. 3D)
and ubiquitin (Fig. 3E) in the ipsilateral nigral neurons.
3. Behavioral impairments
Amphetamine-induced rotational behavior was analyzed to
assess the unilateral degeneration of the presynaptic dopaminergic
neuron terminals. Vehicle-injected rats did not show any
significant bias in turning behavior after receiving an amphet-
amine injection. We did not observe the drug-induced rotational
behavior at one week and two weeks after LPS challenge (data not
shown). However, intrastriatal LPS caused a marked ipsilateral
rotational behavior toward the lesioned side (p=0.031) upon
amphetamine challenge, four weeks after LPS injections (Fig. 4A).
The cylinder test was carried out at one week, two weeks, and
four weeks post- LPS injection to assess an independent forelimb
touch of animals to support their body against a cylinder wall [34].
Pronounced asymmetric forelimb use was developed by unilateral
intrastriatal LPS injection, but not by vehicle injections.
Asymmetric forelimb use was significantly increased at all three
time points (p=0.004, p=0.005, and p=0.013 respectively)
(Fig. 4B).
Figure 3. Cytoplasmic accumulation of a-synuclein and ubiquitin in the nigral TH-positive neurons at four weeks after intrastriatal
LPS. (A) Photomicrograph of double immunofluorescent labeling with antibodies against TH (red) and a-synuclein (green) show that intrastriatal LPS
mediates marked TH-positive cell loss in the substantia nigra ipsilateral to the injection. Scale bar: 100 mm. (B) High magnification images of the top
photograph demonstrate that some of the spared TH-positive neurons have accumulated a-synuclein in their cytoplasm (arrow heads). Scale bar:
20 mm. (C) Immunofluorescent staining displays ubiquitin accumulation in the cytoplasm of the nigral TH-positive neurons (arrow heads). Scale bar:
20 mm. (D–E) Increase of proteinase K-resistant a-synuclein (D) or ubiquitin (E) in the substantia nigra after LPS injection. Scale bar: 50 mm.
doi:10.1371/journal.pone.0005482.g003
Figure 4. Behavioral deficits following intrastriatal LPS. (A)
Ipsilateral rotational behavior in the unilateral LPS-injected animals is
significantly increased relative to vehicle-treated animals when
amphetamine was administered (n=5–6/group; * p,0.05). (B) The
cylinder test revealed that asymmetric forelimb use is increased
significantly after intrastriatal LPS and was sustained for four weeks
(n=5–6/group; ** p,0.01).
doi:10.1371/journal.pone.0005482.g004
Nitric Oxide and Parkinsonism
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intrastriatal LPS injection
We characterized neuroinflammation by immunostaining of
MHC class II (OX-6), a marker for activated microglia and by
measuring the transcriptional induction of proinflammatory
cytokine genes via the RNase protection assay following
intrastriatal LPS injection. We also performed western blot
analysis to see the temporal and regional patterns of iNOS
expression after LPS challenge.
Increased iNOS expression began to be detected 6 hr after
LPS challenge in both the substantia nigra (p=0.035) and
striatum (p=0.021) (Fig. 5A,B). The increased nigral iNOS
immunoreactivity was gradually reduced as time passed, and
returned to control level at three days (p=0.042 at one day, and
p=0.265 at three days), while the increase in striatal iNOS
expression reached a peak at one day and was still prominent at
three days (p=0.007 at one day, and p=0.027 at three days)
(Fig. 5A,B).
Injection of LPS into the striatum markedly increased the
number of OX-6-positive microglia in the striatum at seven days
post injections, and the increased immunoreactivity remained
elevated for four weeks (Fig. 5C, top panel). Immunoreactivity for
OX-6 began to appear in the ipsilateral substantia nigra one week
after LPS injection, peaked at two weeks, and was still prominent
four weeks after LPS (Fig. 5C, bottom panel).
Significant transcriptional increases of IL-1a (p=0.006), TNF-
a (p=0.007), IL-1b (p=0.003), and IL-6 (p=0.001) were
measured in the LPS-treated striatum three hours after LPS
injection. The level of TNF-a mRNA remained significantly
elevated for up to one day (p=0.043) and IL-1b for three days
(p=0.027) after LPS (Fig. S3 a,b). Interestingly, there was a
significant increase in the mRNA expression of IL-1b
(p=3610
24) and IL-6 (p=0.002) in the ipsilateral substantia
nigra, as early as three hours (Fig. S3 c,d).
5. Mitochondrial dysfunction
Intrastriatal LPS induced a significant decrease in nigral (81.3%
of control, p=0.045) and striatal (85.3% of control, p=0.028)
mitochondria state III respiration (the ability to phosphorylate
ADP into ATP), which was efficiently prevented by treatment of
L-NIL (Fig. 6A,B). When using the substrates pyruvate and
malate, in the presence of carbonyl cyanide 4-trifluoromethoxy
phenylhydrazone for maximum (state V) respiration, LPS induced
a significant decrease in complex I activity of both nigral (80.9% of
control, p=0.035) and striatal (81.2% of control, p=0.032)
mitochondria. This impairment in complex I-driven state V
Figure 5. Microglial activation and elevation of iNOS expression in both the substantia nigra and striatum following intrastriatal
LPS injection. The increased iNOS expression occurs at 6 hr post LPS injection, which is sustained for three days in the striatum, and one day in the
substantia nigra (n=3/group, * p,0.05, ** p,0.01 vs. control) (A,B). The OX-6 immunoreactivity in the LPS-injected striatum is markedly increased
one week after LPS injections compared to control or the naı ¨ve side, and immunoreactivity of OX-6 gradually decreased over time. However, the
immunoreactivity is still positive four weeks after LPS (C, top). OX-6-positive microglia appear in the substantia nigra one week after intrastriatal LPS
injection, and the immunoreactivity peaks at two weeks and then decreases to some extent at four weeks (C, bottom). Scale bar: 50 mm.
doi:10.1371/journal.pone.0005482.g005
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When utilizing succinate, the substrate for complex II driven
respiration, state V respiration was also significantly reduced in the
substantia nigra (79.0% of control, p=0.021) and striatum (84.6%
of control, p=0.024) ipsilateral to LPS challenge (Fig. 6A,B). The
reduction in complex II-driven state V respiration was prevented
by treatment with L-NIL. This mitochondrial malfunction was not
as marked as that of a previous study [30], which may reflect wash-
off or severely damaged mitochondria during the isolation, as a
Ficoll gradient method was used here.
6. S-nitrosylation and nitration of mitochondrial complex I
To determine if S-nitrosylation or nitration of mitochondrial
proteins is involved in the neuroinflammation-mediated mito-
chondrial dysfunction, we analyzed the nitration and/or S-
nitrosylation level of mitochondrial complex I. Mitochondrial
function can be compromised by extensive nitration or S-
nitrosylation of mitochondrial complex I [18]. A significant
elevated nitration of complex I (p=0.038) occurred in the
substantia nigra and striatum three days after LPS challenge
(Fig. 7A,B). Treatment with L-NIL efficiently prevented the
increased protein nitration. LPS injection significantly increased in
S-nitrosylation of complex I in the substantia nigra, which was
blocked by L-NIL injection (Fig. 7C,D).
Discussion
Neuroinflammation, mitochondrial dysfunction and selective
loss of dopaminergic neurons have been consistently observed in
the substantia nigra of PD patients [1,6,20]. However, the
correlation among these three in PD remains unclear. Here, we
showed that neuroinflammation is able to mediate mitochondrial
impairment by S-nitrosylation/nitration of mitochondrial proteins.
This is followed by progressive dopaminergic neurodegeneration
in the nigrostriatal system.
The loss of the dopaminergic neurons might be attributable to
the intrinsic sensitivity of dopaminergic neurons to compromised
mitochondrial function. Greenamyre and colleagues reported that
systemic administration of a complex I inhibitor, rotenone to rats
produced a selective degeneration of dopaminergic neurons in the
substantia nigra [23]. Consistent with their report, we recently
found that trichloroethylene causes selective loss of the nigral
dopaminergic neurons in rats via complex I inhibition, and long
term exposure to the chemical may be related to the development
of parkinsonism in a group of factory workers [38]. Furthermore,
mitochondrial dysfunction alone is sufficient to initiate parkinson-
ism in conditional knock-out mice by disrupting the gene for
mitochondrial transcription factor A in the nigral dopamine
neurons [39]. These observations are in agreement with the fact
that rare familial forms of PD are related to mutations in the gene
encoding PINK1 or DJ1, which both regulate mitochondrial
function [40]. Thus, it can be questioned, what makes the nigral
dopaminergic neurons substantially susceptible to mitochondrial
dysfunction. A recent study showed that nigral dopamine neurons
unusually rely on L-type voltage-gated calcium ion channels for
basal activity, and the reliance increases with age [41]. The high
dependency on the calcium channel leads to sustained elevation in
cytosolic calcium concentration, which enhances mitochondrial
respiration, reactive oxygen species generation, and ATP demand
[42–44]. Therefore, the nigral dopaminergic neurons can be
devastated by mitochondrial insults, which are tolerable to the
other populations of neurons.
The implication of NO in PD pathogenesis is supported by the
observations that iNOS expression is upregulated in activated
microglia [11,45], the immunoreactivity of nitrated a-synuclein is
prominently positive in the Lewy bodies [46,47], and several
enzymes including parkin, peroxiredoxin-2, and protein-disul-
phide isomerase lose their function by S-nitrosylation in PD brains
[48–50]. Although association of NO with mitochondrial dys-
function in PD is unclear, NO and its metabolite, peroxynitrite can
compromise mitochondrial biomolecules to induce impairment in
mitochondrial respiration. It has been well known that NO
reversibly inhibit cytochrome c oxidase activity and depletes
mitochondrial antioxidants such as glutathione [51]. Importantly,
peroxynitrite and high level of NO irreversibly inactivates
mitochondrial complex I activity by tyrosine nitration, S-
nitrosylation, oxidation of residues and damage of iron sulfur
center [18,52]. These notions are in agreement with our results
that intrastriatal LPS injection leads to complex I nitration and S-
nitrosylation, and is accompanied decrease in mitochondrial
respiration rate. This evidence strongly supports the hypothesis
that excessive production of NO in the brain might contribute to
mitochondrial dysfunction and subsequent neuronal energy
deficiency observed in PD.
Figure 6. LPS impairs nigrostriatal mitochondria respiration. (A)
Functional impairment occurs in the nigral mitochondria as LPS
significantly decreases state III and state V respiration when driven by
both complex I and complex II substrates. Treatment of L-NIL, an iNOS
inhibitor prevents LPS-induced mitochondrial dysfunction (n=6/group;
*p ,0.05, ** p,0.01 vs. saline+saline, # p,0.05, ## p,0.01 vs.
saline+LPS). (B) It appears that there is a significant decrease in state III
and state V respiration of striatal mitochondria when driven by both
complex I and complex II substrates in the striatum ipsilateral to LPS
injection. L-NIL efficiently blocks the neuroinflammation-mediated
defect in striatal mitochondrial respiration (n=9/group; * p,0.05, **
p,0.01 vs. Saline+Saline, # p,0.05, ## p,0.01 vs. Saline+LPS).
doi:10.1371/journal.pone.0005482.g006
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release of glutamate and consequent excitotoxicity [53]. It has
been reported that neuronal NOS (nNOS)-derived NO accounts,
at least in part, for glutamate-induced excitotoxicity [54]. We
found that activated microglia appears one week after LPS
challenge, and the microgliosis were sustained for four weeks in the
substantia nigra. In addition, we observed that treatment of L-
N(G)-nitro-arginine, an inhibitor of nNOS, was also neuroprotec-
tive against intrastriatal LPS in mice, suggesting the possible
contribution of nNOS to the dopamine neurodegeneration [55].
This is further supported by our observation of cytoplasmic
accumulation of a-synuclein and ubiquitin in the nigral dopamine-
producing neurons, as extensive nitrosative/oxidative stress might
cause impairment of the ubiquitin proteasome system resulting in
accumulation of misfolded proteins [50,56]. Support to the notion
comes from the result that the accumulation of a-synuclein was
attenuated by treatment with L-NIL (unpublished data). Hence,
our results might be relevant for the molecular pathway for Lewy
body formation and PD pathogenesis.
It is interesting that loss of a relatively small population of nigral
dopamine neurons caused a decrease in the striatal dopamine level
and behavioral impairment in the LPS-treated animals. The
behavioral deficit began even at early time-point like one week
following LPS injection. This phenomenon may suggest that the
striatal inflammation antagonizes the function of the dopaminergic
nigrostriatal pathway via altering synthesis and/or release of
dopamine, or by modulating dopamine-mediated signal transduc-
tion before a significant demise of the dopaminergic neurons
occurs. In support of this suggestion, it was shown that MPTP
treatment induces striatal TH nitration, which was related to
inactivation of the enzyme and a subsequent greater decline in
dopamine level, compared to the loss of the dopaminergic neurons
[57]. In addition, direct injection of proinflammatory mediators
into the striatum such as prostaglandin D2 and the thromboxane
A2 agonist induced impairment of motor behavior; although, the
specific mechanism was not elucidated [58,59]. Therefore, further
study is required to fully illuminate the mechanism by which
neurochemical alterations and behavioral deficit occur following
intrastriatal LPS injections.
Taken together, results of the present study provide strong
support to the hypothesis that neuroinflammation may signifi-
cantly contribute to PD pathogenesis. This animal model may be
useful for studying neuroinflammatory mechanisms by which
nigral dopamine neurons degenerate in PD.
Supporting Information
Figure S1 LPS-induced neuroinflammation significantly de-
creases TH-positive fiber density in the striatum four weeks after
LPS challenge (n=5/group, *** p,0.001 vs. control).
Found at: doi:10.1371/journal.pone.0005482.s001 (2.50 MB TIF)
Figure S2 Decrease in striatal serotonin level following LPS
injection. HPLC analysis reveals that intrastriatal LPS injection
significantly reduces serotonin level, but not its metabolite 5-HIAA
resulting in marked elevation of the turnover ratio (5-HIAA/
serotonin) (n=7/group, *** p,0.001 vs. control).
Found at: doi:10.1371/journal.pone.0005482.s002 (2.59 MB TIF)
Figure S3 The elevated mRNA levels of proinflammatory
cytokines in the striatum and substantia nigra. (A,B) RPA shows
that the mRNA of the proinflammatory cytokines TNF-alpha, and
IL-1beta begin to significantly increase three hours after LPS
injections in the striatum, compared to the naı ¨ve or vehicle treated
striatum, which is sustained for up to three days following LPS.
The elevated mRNA levels of IL-1alpha and IL-6 occur three
hours after LPS injection in the striatum, compared to the naı ¨ve or
vehicle treated striatum, and return to control level at six hours
following LPS (n=4/group; * p,0.05, ** p,0.01). (C,D) RPA
demonstrates that mRNA levels of IL-1beta and IL-6 are
significantly increased in the substantia nigra three hours after
LPS injection and remain significantly increased for six hours,
when compared with the naı ¨ve or vehicle treated substantia nigra.
IL-1alpah and TNF-alpha only show a trend to be increased at the
three hour time point (n=4/group; * p,0.05, ** p,0.01).
Figure 7. Nitration/S-nitrosylation of mitochondrial complex I after intrastriatal LPS. Intrastriatal LPS injection increases 3-nitrotyrosine (3-
NT) level in complex I three days after LPS injection. Treatment with L-NIL appears to prevent the LPS-induced elevation of mitochondrial protein
nitration (A,B). Isolated nigral and striatal mitochondria complex I proteins have an increase in S-nitrosylation three days after LPS injection. L-NIL
treatment appears to prevent the LPS-induced increase of S-nitrosylation (C,D). S+S: saline treated and saline injected; S+L: saline-treated and LPS-
injected; N+S: L-NIL-treated and saline-injected; and N+L: L-NIL-treated and LPS-injected; SN: substantia nigra (n=4/group; * p,0.05 vs. S+S, and #
p,0.05, p,0.01 vs. S+L).
doi:10.1371/journal.pone.0005482.g007
Nitric Oxide and Parkinsonism
PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5482Found at: doi:10.1371/journal.pone.0005482.s003 (5.90 MB TIF)
Acknowledgments
We are grateful to Ms. Laura Peters for the excellent technical support of
HPLC analysis.
Author Contributions
Conceived and designed the experiments: DYC RLH HCK GB.
Performed the experiments: DYC ML WAC JDP EJS. Analyzed the data:
DYC RLH JDP EJS DMG GB. Contributed reagents/materials/analysis
tools: PGS. Wrote the paper: DYC RLH. Quality control: DMG.
References
1. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are
positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s
disease brains. Neurology 38: 1285–1291.
2. Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, et al. (1999)
Activated macrophages and microglia induce dopaminergic sprouting in the
injured striatum and express brain-derived neurotrophic factor and glial cell line-
derived neurotrophic factor. J Neurosci 19: 1708–1716.
3. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of
microglia. Glia 7: 111–118.
4. Gehrmann J, Banati RB, Wiessner C, Hossmann KA, Kreutzberg GW (1995)
Reactive microglia in cerebral ischaemia: an early mediator of tissue damage?
Neuropathol Appl Neurobiol 21: 277–289.
5. Banati RB, Daniel SE, Blunt SB (1998) Glial pathology but absence of apoptotic
nigral neurons in long-standing Parkinson’s disease. Mov Disord 13: 221–227.
6. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity:
uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57–69.
7. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, et al. (1999) Evidence
of active nerve cell degeneration in the substantia nigra of humans years after 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598–605.
8. McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive
microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine administration. Ann Neurol 54: 599–604.
9. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, et al. (2005)
Microglial activation and dopamine terminal loss in early Parkinson’s disease.
Ann Neurol 57: 168–175.
10. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, et al. (2005)
Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease.
Ann Neurol 58: 963–967.
11. Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson’s
disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci
16: 724–739.
12. Arimoto T, Bing G (2003) Up-regulation of inducible nitric oxide synthase in the
substantia nigra by lipopolysaccharide causes microglial activation and
neurodegeneration. Neurobiol Dis 12: 35–45.
13. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, et al. (1999)
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in
the MPTP model of Parkinson disease. Nat Med 5: 1403–1409.
14. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, et al. (2003) Cyclooxygenase-
2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad
Sci U S A 100: 5473–5478.
15. Bal-Price A, Brown GC (2001) Inflammatory neurodegeneration mediated by
nitric oxide from activated glia-inhibiting neuronal respiration, causing
glutamate release and excitotoxicity. J Neurosci 21: 6480–6491.
16. Radi R (2004) Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl
Acad Sci U S A 101: 4003–4008.
17. Tangpong J, Cole MP, Sultana R, Estus S, Vore M, et al. (2007) Adriamycin-
mediated nitration of manganese superoxide dismutase in the central
nervous system: insight into the mechanism of chemobrain. J Neurochem 100:
191–201.
18. Brown GC, Borutaite V (2004) Inhibition of mitochondrial respiratory complex
I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim Biophys Acta 1658:
44–49.
19. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, et al. (1989)
Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1: 1269.
20. Schapira AH (2007) Mitochondrial dysfunction in Parkinson’s disease. Cell
Death Differ 14: 1261–1266.
21. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in
humans due to a product of meperidine-analog synthesis. Science 219: 979–980.
22. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in
human and non-human primates--clinical and experimental aspects. Acta
Neurol Scand Suppl 100: 49–54.
23. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al.
(2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s
disease. Nat Neurosci 3: 1301–1306.
24. Antunes F, Han D, Rettori D, Cadenas E (2002) Mitochondrial damage by nitric
oxide is potentiated by dopamine in PC12 cells. Biochim Biophys Acta 1556:
233–238.
25. Cohen G, Kesler N (1999) Monoamine oxidase and mitochondrial respiration.
J Neurochem 73: 2310–2315.
26. Herrera AJ, Castano A, Venero JL, Cano J, Machado A (2000) The single
intranigral injection of LPS as a new model for studying the selective effects of
inflammatory reactions on dopaminergic system. Neurobiol Dis 7: 429–447.
27. Hsieh PF, Chia LG, Ni DR, Cheng LJ, Ho YP, et al. (2002) Behavior,
neurochemistry and histology after intranigral lipopolysaccharide injection.
Neuroreport 13: 277–280.
28. Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV, et al. (2007) Interleukin-10
protects against inflammation-mediated degeneration of dopaminergic neurons
in substantia nigra. Neurobiol Aging 28: 894–906.
29. Zhang J, Stanton DM, Nguyen XV, Liu M, Zhang Z, et al. (2005) Intrapallidal
lipopolysaccharide injection increases iron and ferritin levels in glia of the rat
substantia nigra and induces locomotor deficits. Neuroscience 135: 829–838.
30. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, et al. (2007)
Inflammation induces mitochondrial dysfunction and dopaminergic neurode-
generation in the nigrostriatal system. J Neurochem 100: 1375–1386.
31. Liu M, Hunter R, Nguyen XV, Kim HC, Bing G (2008) Microsomal epoxide
hydrolase deletion enhances tyrosine hydroxylase phosphorylation in mice after
MPTP treatment. J Neurosci Res 86: 2792–2801.
32. Georgievska B, Carlsson T, Lacar B, Winkler C, Kirik D (2004) Dissociation
between short-term increased graft survival and long-term functional improve-
ments in Parkinsonian rats overexpressing glial cell line-derived neurotrophic
factor. Eur J Neurosci 20: 3121–3130.
33. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF (2003) HIV-1 protein
Tat potentiation of methamphetamine-induced decreases in evoked overflow of
dopamine in the striatum of the rat. Brain Res 984: 133–142.
34. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, et al. (2002)
Pharmacological validation of behavioural measures of akinesia and dyskinesia
in a rat model of Parkinson’s disease. Eur J Neurosci 15: 120–132.
35. Brown MR, Sullivan PG, Geddes JW (2006) Synaptic mitochondria are more
susceptible to Ca2+overload than nonsynaptic mitochondria. J Biol Chem 281:
11658–11668.
36. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990)
Compensations after lesions of central dopaminergic neurons: some clinical and
basic implications. Trends Neurosci 13: 290–296.
37. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophys-
iology of Parkinson’s disease. Annu Rev Neurosci 28: 57–87.
38. Gash DM, Rutland K, Hudson NL, Sullivan PG, Bing G, et al. (2008)
Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity.
Ann Neurol 63: 184–192.
39. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, et al. (2007)
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine
neurons. Proc Natl Acad Sci U S A 104: 1325–1330.
40. Schapira AH (2006) Mitochondrial disease. Lancet 368: 70–82.
41. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, et al. (2007) ‘Rejuvenation’
protects neurons in mouse models of Parkinson’s disease. Nature 447:
1081–1086.
42. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in
Parkinson’s disease. Science 302: 819–822.
43. Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models.
Neuron 39: 889–909.
44. Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the
calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552–565.
45. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, et al. (1996)
Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease.
Neuroscience 72: 355–363.
46. Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, et al. (2000) Widespread
nitration of pathological inclusions in neurodegenerative synucleinopathies.
Am J Pathol 157: 1439–1445.
47. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative
damage linked to neurodegeneration by selective alpha-synuclein nitration in
synucleinopathy lesions. Science 290: 985–989.
48. Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA (2007) S-nitrosylation of
peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in
Parkinson’s disease. Proc Natl Acad Sci U S A 104: 18742–18747.
49. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, et al. (2004) S-
nitrosylation of parkin regulates ubiquitination and compromises parkin’s
protective function. Science 304: 1328–1331.
50. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, et al. (2006) S-nitrosylated
protein-disulphide isomerase links protein misfolding to neurodegeneration.
Nature 441: 513–517.
51. Moncada S, Bolanos JP (2006) Nitric oxide, cell bioenergetics and neurodegen-
eration. J Neurochem 97: 1676–1689.
52. Clementi E, Brown GC, Feelisch M, Moncada S (1998) Persistent inhibition of
cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial
complex I and protective action of glutathione. Proc Natl Acad Sci U S A 95:
7631–7636.
Nitric Oxide and Parkinsonism
PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e548253. Barger SW, Basile AS (2001) Activation of microglia by secreted amyloid
precursor protein evokes release of glutamate by cystine exchange and attenuates
synaptic function. J Neurochem 76: 846–854.
54. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH (1991) Nitric
oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl
Acad Sci U S A 88: 6368–6371.
55. Hunter RL, Cheng B, Choi DY, Liu M, Liu S, et al. (2009) Intrastriatal
lipopolysaccharideinjectioninducesParkinsonisminC57/B6miceJNeurosciRes.
56. McNaughtKS,OlanowCW,HalliwellB,IsacsonO,JennerP(2001)Failureofthe
ubiquitin-proteasomesysteminParkinson’sdisease.NatRevNeurosci2:589–594.
57. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, et al. (1998)
Inactivation of tyrosine hydroxylase by nitration following exposure to
peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc
Natl Acad Sci U S A 95: 7659–7663.
58. Costall B, Holmes SW, Kelly ME, Naylor RJ (1985) Modification of dyskinesias
following the intrastriatal injection of prostaglandins in the rodent.
Br J Pharmacol 85: 943–949.
59. Yagami T, Takahara Y, Ishibashi C, Sakaguchi G, Itoh N, et al. (2004) Amyloid
beta protein impairs motor function via thromboxane A2 in the rat striatum.
Neurobiol Dis 16: 481–489.
Nitric Oxide and Parkinsonism
PLoS ONE | www.plosone.org 11 May 2009 | Volume 4 | Issue 5 | e5482